Vše

Co hledáte?

Vše
Projekty
Výsledky výzkumu
Subjekty

Rychlé hledání

  • Projekty podpořené TA ČR
  • Významné projekty
  • Projekty s nejvyšší státní podporou
  • Aktuálně běžící projekty

Chytré vyhledávání

  • Takto najdu konkrétní +slovo
  • Takto z výsledků -slovo zcela vynechám
  • “Takto můžu najít celou frázi”

Comparison of lymphocyte immune phenotypes in bronchoalveolar lavage of non-smoking patients with sarcoidosis and other interstitial lung diseases

Identifikátory výsledku

  • Kód výsledku v IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F19%3A73598463" target="_blank" >RIV/61989592:15110/19:73598463 - isvavai.cz</a>

  • Výsledek na webu

    <a href="http://jtd.amegroups.com/article/view/29635/21451" target="_blank" >http://jtd.amegroups.com/article/view/29635/21451</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.21037/jtd.2019.06.05" target="_blank" >10.21037/jtd.2019.06.05</a>

Alternativní jazyky

  • Jazyk výsledku

    angličtina

  • Název v původním jazyce

    Comparison of lymphocyte immune phenotypes in bronchoalveolar lavage of non-smoking patients with sarcoidosis and other interstitial lung diseases

  • Popis výsledku v původním jazyce

    Background: Bronchoalveolar lavage (BAL) as complementary method is still used as ancillary tool in diagnosis of interstitial lung diseases. lbbacco smoking has been described to affect the BAL, lavage cellular profile. lb our knowledge, only few reports have so far investigated CD3(+)CD4(+) and CD3(+)CD8(+) lymphocyte subsets in non-smoking sarcoidosis patients additionally stratified according to CXR stage, and compared them to other non-smoking patients with interstitial lung diseases (ILDs). Methods: We compared lymphocytes immune phenotypes, subsets, with CD3(+), CD3(+)CD4(+) and CD3(+)TD8(+) cell markers, in the non-smoking subjects (n=297) including the patients with pulmonary sarcoidosis (S), idiopathic pulmonary fibrosis (IPF) (n=22), hypersensitivity pneumonitis (HP) (n=15), other interstitial idiopathic pneumonias (OIIPs) (n=39). According to prognosis, the patients with S were divided into four groups: 18 patients with Lofgren&apos;s syndrome (LS) in chest X-ray (CXR) &lt;= 1 stage, 64 patients without LS in CXR &lt;= 1 stage, 113 patients in CXR 2 stage and 26 patients with advanced CXR &gt;= 3 stage. Results: After the use of false discovery rate (FDR) correction, relative numbers (%) of CD3(+), CD3(+)CD4(+), CD3(+)CD8(+) and CD3(+)CD4(+)/CD3(+)CD8(+) ratio showed the most significant differences between the nonsmokers with S (both with/without LS) and the non-smokers with other ILDs (IPF, OIIPs, HP). These lymphocytes subsets were further altered in the non-smokers with CXR stage 2 compared to the nonsmokers with other ILDs (IPF, OIIPs, HP). We did not observe any differences in these lymphocyte subsets and CD3(+)CD4(+)/CD3(+)CD8(+). ratio between the non-smokers with advanced sarcoidosis stage (CXR &gt;= 3) and the non-smokers with IPF. Conclusions: Our data on the non-smokers confirmed the presence of the typical BAL cellular profile in sarcoidosis. The BAL cellular profile was helpful namely for differentiation of less advanced sarcoidosis. Its definite diagnostic utility should be the subject of further clinical studies with large numbers of the well characterized patients taking into consideration other clinical factors influencing BAL, cellular profile, such as smoking or treatment.

  • Název v anglickém jazyce

    Comparison of lymphocyte immune phenotypes in bronchoalveolar lavage of non-smoking patients with sarcoidosis and other interstitial lung diseases

  • Popis výsledku anglicky

    Background: Bronchoalveolar lavage (BAL) as complementary method is still used as ancillary tool in diagnosis of interstitial lung diseases. lbbacco smoking has been described to affect the BAL, lavage cellular profile. lb our knowledge, only few reports have so far investigated CD3(+)CD4(+) and CD3(+)CD8(+) lymphocyte subsets in non-smoking sarcoidosis patients additionally stratified according to CXR stage, and compared them to other non-smoking patients with interstitial lung diseases (ILDs). Methods: We compared lymphocytes immune phenotypes, subsets, with CD3(+), CD3(+)CD4(+) and CD3(+)TD8(+) cell markers, in the non-smoking subjects (n=297) including the patients with pulmonary sarcoidosis (S), idiopathic pulmonary fibrosis (IPF) (n=22), hypersensitivity pneumonitis (HP) (n=15), other interstitial idiopathic pneumonias (OIIPs) (n=39). According to prognosis, the patients with S were divided into four groups: 18 patients with Lofgren&apos;s syndrome (LS) in chest X-ray (CXR) &lt;= 1 stage, 64 patients without LS in CXR &lt;= 1 stage, 113 patients in CXR 2 stage and 26 patients with advanced CXR &gt;= 3 stage. Results: After the use of false discovery rate (FDR) correction, relative numbers (%) of CD3(+), CD3(+)CD4(+), CD3(+)CD8(+) and CD3(+)CD4(+)/CD3(+)CD8(+) ratio showed the most significant differences between the nonsmokers with S (both with/without LS) and the non-smokers with other ILDs (IPF, OIIPs, HP). These lymphocytes subsets were further altered in the non-smokers with CXR stage 2 compared to the nonsmokers with other ILDs (IPF, OIIPs, HP). We did not observe any differences in these lymphocyte subsets and CD3(+)CD4(+)/CD3(+)CD8(+). ratio between the non-smokers with advanced sarcoidosis stage (CXR &gt;= 3) and the non-smokers with IPF. Conclusions: Our data on the non-smokers confirmed the presence of the typical BAL cellular profile in sarcoidosis. The BAL cellular profile was helpful namely for differentiation of less advanced sarcoidosis. Its definite diagnostic utility should be the subject of further clinical studies with large numbers of the well characterized patients taking into consideration other clinical factors influencing BAL, cellular profile, such as smoking or treatment.

Klasifikace

  • Druh

    J<sub>imp</sub> - Článek v periodiku v databázi Web of Science

  • CEP obor

  • OECD FORD obor

    30203 - Respiratory systems

Návaznosti výsledku

  • Projekt

    Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

  • Návaznosti

    P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Ostatní

  • Rok uplatnění

    2019

  • Kód důvěrnosti údajů

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Údaje specifické pro druh výsledku

  • Název periodika

    Journal of Thoracic Disease

  • ISSN

    2072-1439

  • e-ISSN

  • Svazek periodika

    11

  • Číslo periodika v rámci svazku

    6

  • Stát vydavatele periodika

    HK - Hongkong

  • Počet stran výsledku

    10

  • Strana od-do

    2287-2296

  • Kód UT WoS článku

    000473287500023

  • EID výsledku v databázi Scopus

    2-s2.0-85068935445